While reporting improved second-quarter numbers, Novartis says that it is considering new acquisitions in healthcare as it faces increased competition from generic drugs. With Lortel and Lamisil likely to hijack some of its revenue, Novartis is also dealing with the market suspension of Zelnorm. Report